Evidence map›Paper›PMID 33334146›Full record

ArticleDiabetes & vascular disease research

Maturity onset diabetes of the young and fibrin-related thrombosis risk.

R C Sagar, F Phoenix, G Thanabalasingham, K Naseem, R A Ajjan, K R Owen

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes & vascular disease research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact, top 72% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

R C SagarLeeds Institute of Cardiovascular and Metabolic Medicine, Faculty of Medicine and Health, University of Leeds, Leeds, West Yorkshire, UK.ORCID 0000-0001-7972-3321
F PhoenixLeeds Institute of Cardiovascular and Metabolic Medicine, Faculty of Medicine and Health, University of Leeds, Leeds, West Yorkshire, UK.
G ThanabalasinghamOxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK.
K NaseemLeeds Institute of Cardiovascular and Metabolic Medicine, Faculty of Medicine and Health, University of Leeds, Leeds, West Yorkshire, UK.
R A AjjanLeeds Institute of Cardiovascular and Metabolic Medicine, Faculty of Medicine and Health, University of Leeds, Leeds, West Yorkshire, UK.
K R OwenOxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK.
University of Leeds · GBChurchill Hospital · GBUniversity of Oxford · GB

Funding

British Heart Foundation FS/19/45/34443
6 · The paper itself

Abstract

backgroundFibrin network characteristics determine predisposition to cardiovascular disease (CVD). Individuals with type 1 (T1DM) and type 2 diabetes mellitus (T2DM) have higher risk of CVD and display deranged fibrin network structure. Those with maturity onset diabetes of the young (MODY) may also be at increased risk but their fibrin clot properties have not been studied.

methodsPlasma clots properties from 13 individuals with HNF1A-MODY, 12 matched-individuals with T2DM and 12 with T1DM were studied using a validated turbidimetric assay and confocal microscopy. Plasma levels of fibrinogen, plasminogen activator inhibitor-1, complement C3 and C-reactive protein were also measured.

resultsMODY clot maximum absorbance was 0.37 ± 0.03 AU, similar to T1DM (0.32 ± 0.03 AU;

conclusionsHNF1A-MODY fibrin network alterations are at least as pronounced as in T1DM but less thrombotic than T2DM clots. Differences in fibrin clot characteristics comparing HNF1A-MODY and T2DM may, in part, relate to lower C3 levels.

Indexed as

AdultBiomarkersComplement C3C-Reactive ProteinDiabetes Mellitus, Type 2FemaleFibrinGenetic Predisposition to DiseaseHepatocyte Nuclear Factor 1-alphaHumansMaleMiddle AgedPilot ProjectsPlasminogen Activator Inhibitor 1Risk FactorsThrombosisBiomarkersC3 protein, humanComplement C3C-Reactive ProteinFibrinHepatocyte Nuclear Factor 1-alphaHNF1A protein, humanPlasminogen Activator Inhibitor 1SERPINE1 protein, humanclot structurefibrinolysisMODYthrombosis

Identifiers

PMID33334146
PMCPMC7919224
OpenAlexW3116275128

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.